News Conferences at American Heart Association’s Scientific Sessions 2009

SUNDAY, NOV. 15
8-9:30 am ET Sunday, Nov. 15
Late-breaking Clinical Trials I (LBCT.01) – Platelets
Embargo for each lifts at the start of the news conference

• Moderator: Clyde Yancy, M.D., American Heart Association President

• Presenter: Nicoline J. Breet, M.D., St. Antonius Hosp Nieuwegein, Netherlands
First Prospective Comparison Between Platelet Function Tests in Prediction Clinical Outcome in 1,100 Patients Undergoing Coronary Stent Placement (POPULAR)
POPULAR is a prospective trial to assess which platelet function test is best to predict atherothrombotic events in patients treated with aspirin and clopidogrel undergoing PCI with stent implantation.
• Discussant: Franz J. Neumann, M.D., Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

• Presenter: Robert A. Harrington, M.D., Duke Clinical Res Inst, Durham, N.C.
The Results of the CHAMPION PCI Trial
The CHAMPION PCI trial will help determine the efficacy and safety of cangrelor versus pretreatment with a 600 mg loading dose of clopidogrel. These results may help define the necessary amount of ADP inhibition for PCI.
• Discussant: Alan Michelson, M.D., Children’s Hospital Boston, Boston, Mass.

• Presenter: Deepak L. Bhatt, M.D., M.P.H., VA Boston Healthcare Sys; Brigham & Women’s Hosp, Boston, Mass.
The Results of the CHAMPION PLATFORM Trial
The CHAMPION PLATFORM trial will help determine the efficacy and safety of potent procedural ADP receptor antagonism with cangrelor versus a 600 mg loading dose of clopidogrel given immediately after the procedure. In addition to important information about cangrelor, these results may help determine the relative merits of the timing of clopidogrel loading.
• Discussant: David P. Faxon, M.D., Brigham and Women’s Hosp., Boston, Mass.

• Presenter: P. Gabriel Steg, INSERM Paris, France
Comparison of Ticagrelor, the First Reversible Oral P2Y12 Receptor Antagonist, with Clopidogrel in Patients with ST-Elevation Acute Coronary Syndromes: Results from the PLATelet Inhibition and Patient Outcomes (PLATO) Trial
The PLATO trial tested whether ticagrelor is superior to clopidogrelin in preventing vascular events in patients with either non-ST-elevation ACS or ST-elevation ACS with planned primary percutaneous coronary intervention (PCI).
• Discussant: Lisa K. Jennings, Ph.D. University of Tennessee Health Science Center, Memphis, Tenn.